West Pharmaceutical (WST) Services announced that Eric Green has informed the Board of Directors that he plans to retire from his positions as President, CEO and Chair of the Board of the company once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026. In parallel with today’s announcement, the company is reaffirming the guidance set forth in its February 12 press release.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- Customer Concentration Risk: How Dependence on Key Accounts Threatens West Pharmaceutical’s Financial Stability
- West Pharmaceutical announces new $1B share repurchase program
- West Pharmaceutical price target lowered to $300 from $370 at BofA
- West Pharmaceutical price target lowered to $340 from $355 at UBS
- West Pharmaceutical price target raised to $315 from $310 at Deutsche Bank